Skip to main content
ADTX
NASDAQ Life Sciences

Aditxt Chairman and General Counsel Resign Amid Delisting Threat and Going Concern Warning

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$0.06
Mkt Cap
$50.669K
52W Low
$0.056
52W High
$53,450.606
52W Position info
6.4% above low
Off High info
100% below high
Rel. Volume info
6.8× avg
Market data snapshot near publication time

ADTX is trading near its 52-week low of $0.056 (6.4% above the low) on elevated volume (6.8× avg).

Summary

Aditxt, Inc. announced the immediate resignations of its non-executive Chairman of the Board and its General Counsel, Chief People Officer, and Corporate Secretary, adding to concerns for the company already facing delisting and a 'going concern' warning.


Key Events · Executive and Board Changes · ADTX

  • Chairman of the Board Resigns

    Brian Brady resigned as non-executive Chairman of the Board and as a member of the Board, effective June 2, 2026. Mr. Brady also served as Chair of the Audit Committee and was a member of the Compensation and Nominating and Corporate Governance Committees.

  • General Counsel and CPO Resigns

    Christopher J. Porcelli resigned as General Counsel, Chief People Officer, and Corporate Secretary, effective June 2, 2026.


Analysis · ADTX · Life Sciences

The resignations of the non-executive Chairman of the Board (who also chaired the Audit Committee) and the General Counsel/Chief People Officer are critical. These departures signal a significant loss of leadership and governance expertise at a time when Aditxt is facing severe financial distress, a Nasdaq delisting notice, and a 'going concern' warning. Such high-level exits can further erode investor confidence and complicate efforts to address the company's existential challenges.

How filings like this one have moved

In the 30 days to Sep 27, 2026, 42.3% of the 312 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.48%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ADTX was trading at $0.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50.7K. The 52-week trading range was $0.06 to $53,450.61. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADTX - Latest Insights

ADTX
Sep 23, 2026, 11:34 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.00416
Real-time Price: $0.0046 info
Change: +$0.00044 (+11%) info
Market Cap: $4.591M info
ADTX
Aug 19, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.0022
Real-time Price: $0.0046 info
Change: +$0.0024 (+109%) info
Market Cap: $4.591M info
ADTX
Jul 17, 2026, 12:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.0025
Real-time Price: $0.0046 info
Change: +$0.0021 (+84%) info
Market Cap: $4.591M info
ADTX
Jun 24, 2026, 11:36 AM EDT
Filing Type: 8-K
Importance Score:
10
Price at Filing: $0.050599
Real-time Price: $0.0046 info
Change: -$0.045999 (-91%) info
Market Cap: $4.591M info
ADTX
Jun 24, 2026, 3:13 AM EDT
Source: Wiseek News
Importance Score:
9
Price at Filing: $0.0406
Real-time Price: $0.0046 info
Change: -$0.036 (-89%) info
Market Cap: $4.591M info